;){kind=link}
Mr. Liu
Address:
No. 111 Qinling Street, Shijiazhuang, Hebei, China
Telephone:
Zip Code:
Fax:
| Please sign in to view contact details |
Account Registered in:
2020
Business Range:
Chemicals, Health & Medicine
Business Type:
Manufacturer/Factory, Trading Company, Group Corporation
Company Introduction
Production Capacity
CSPC is listed in Top 10 Asian Pharmaceutical Companiesin Sales Revenue, and its products are sold throughout China and more than 60 countries and regions in the world. In 2018, Institutional Investor, an international authoritative financial magazine, presented the latest annual ranking list in which CSPC was awarded The Most Respected Enterprise in the rating ofCompany Management Team in Asia ...
CSPC is listed in Top 10 Asian Pharmaceutical Companiesin Sales Revenue, and its products are sold throughout China and more than 60 countries and regions in the world. In 2018, Institutional Investor, an international authoritative financial magazine, presented the latest annual ranking list in which CSPC was awarded The Most Respected Enterprise in the rating ofCompany Management Team in Asia 2018. In 2017, the total export value reached to USD 600 million and CSPC ranked first among China's exports of health care products.
At present, CSPC is promoting its internationalization strategy by creative work at ANDA, new medicine application and meeting the international quality standards.
CSPC aims at imitation generic drug of high barrier species generic drug. Up to now, 16 medicines have been approved by ANDA.
Meanwhile, NDA is accelerated. NBP has completed Phase clinical trials in the USA. NBP, Mitoxantrone hydrochloride liposome injection and the gastric cancer drug "DP303c" are being developed in the USA as orphan-drug designation.
At present, CSPC is promoting its internationalization strategy by creative work at ANDA, new medicine application and meeting the international quality standards.
CSPC aims at imitation generic drug of high barrier species generic drug. Up to now, 16 medicines have been approved by ANDA.
Meanwhile, NDA is accelerated. NBP has completed Phase clinical trials in the USA. NBP, Mitoxantrone hydrochloride liposome injection and the gastric cancer drug "DP303c" are being developed in the USA as orphan-drug designation.
Factory Address:
No. 111 Qinling Street, Shijiazhuang, Hebei, China